However, when it comes to chronic ailments like osteoporosis, the “Trial-and-Error” methods mentioned above do not work out. There needs to be specificity regarding the same. By drug class, osteoporosis drugs could be categorized into SERM (Selective Estrogen Inhibitors Modulator), bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and others). By route of administration, these drugs could be segregated as injectable, oral, and others. Out of these SERM is expected to define the growth for osteoporosis drugs market going forward.
In case of women, premenopausal osteoporosis is common. The premenopausal osteoporosis therapeutics market, by type, consists of hormones, bisphonates, strontium ranelate, raloxifene, and denosumab. Bisphonates dominate the market.
Coming to psoriasis, there have been numerous experiments – right from the slow-paced homeopathy to fast-paced allopathy. By therapeutic class, the psoriasis drugs market spans tumor necrosis factor inhibitor, interleukin inhibitors, and others. By treatment, it’s systemic, topicals, and biologics.
Out of these, Interleukin inhibitors are expected to grow at the fastest rate in the near future with increasing adoption amongst the end-users in the form of Talz (ixekizumab), Cosentyx (secukinumab), Ilumya (tildrakizumab), Siliq (brodalumab), and Tremfya (guselkumab). Likewise, plague psoriasis treatment market is expected to pick up pace with systemic agents, phototherapy, topical therapy, and biologic therapies. Topical therapy holds the largest market share.
Persistence Market Research (PMR) has, in its market study named “Drugs Diagnostics market”, has looked through the geographies like North America, Europe, the Asia-Pacific, LATAM, and MEA. PMR has mentioned that North America is at the forefront in this regard, followed by the Europe, and also the fact that the Asia-Pacific is expected to witness the highest growth rate with increasing penetration of advanced therapeutics herein.
Besides, Persistence Market Research has brought to the notice that the developing economies of the Asia-Pacific needs to come out of the “awkwardness” regarding getting treated for postmenopausal osteoporosis, as the topic of “menstruation” isn’t that openly discussed over here except for the metro cities. Once that hesitation gets weaned off, the Asia-Pacific will prove to be the good source of revenue on this count as well.
Persistence Market Research (PMR) has profiled the key players like AstraZeneca, Novartis AG, AbbVie Inc., Johnson & Johnson, Amgen Inc., Eli Lilly & Company, LEO Pharma, Celgene Corporation, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche AG, and Merck & Co. Inc. It has also harped on the fact that in the US the medications approved for treating postmenopausal osteoporosis include risedronate, bisphosphonates alendronate, and ibandronate.